GenoMed Partners with Jennifer’s Pharmacy in Clayton, MO


David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938

Jennifer Rich RPh
CEO, Jennifer’s Pharmacy
Tel. 314.862.7400

ST. LOUIS—July 8, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it has partnered with Jennifer’s Pharmacy of Clayton, Missouri, a suburb of St. Louis as part of GenoMed’s plan to make the US dialysis-free by 2014 (

Jennifer’s Pharmacy will educate its customers with type 2 diabetes, high blood pressure, as well as emphysema about GenoMed’s Clinical Outcomes Improvement Program (COIP®).

David W. Moskowitz, MD FACP, GenoMed’s CEO and Chief Medical Officer, said “Education is key if we are to prevent kidney failure. We’re delighted that Jennifer’s Pharmacy is as eager as we are to serve their clients’ health needs. We look forward to a long and fruitful association with Jennifer’s Pharmacy and their clients.”

Said Jennifer Rich, RPh, CEO of Jennifer’s Pharmacy, “We’re happy to do our part to help our customers live a healthier and longer life. Being healthy also means preventing future health problems. We are excited to be able to work with Dr. Moskowitz.”

About GenoMed

GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™ in the world, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere on earth. Please contact Dr. Moskowitz (see above for contact info) if you have one of these diseases.

About Jennifer’s Pharmacy & Soda Shoppe

As the only independent retail pharmacy in the city of Clayton, Missouri, Jennifer’s Pharmacy has already attracted a strong and loyal following.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.